"SANKYO" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year p...
Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan Fierce Pharma
Daiichi Sankyo unveils new five-year business plan - The Pharma Letter
Daiichi Sankyo unveils new five-year business plan The Pharma Letter
Daiichi Sankyo Targets Global Top Five Oncology Position By 2035 - BioPharma APAC
Daiichi Sankyo Targets Global Top Five Oncology Position By 2035 BioPharma APAC
Daiichi's ADC miscalculation leads to compensation of over $480M to CMOs - FirstWord Pharma
Daiichi's ADC miscalculation leads to compensation of over $480M to CMOs FirstWord Pharma
Daiichi Sankyo posts Q4 revenue growth but reports operating loss - Investing.com
Daiichi Sankyo posts Q4 revenue growth but reports operating loss Investing.com
Daiichi Sankyo Company, Limited 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:DSNKY) 20...
Daiichi Sankyo Company, Limited 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:DSNKY) 2026-05-11 Seeking Alpha
Daiichi Sankyo 4Q Japan Business Unit Revenue Y95.0B Vs Y91.2B - Moomoo
Daiichi Sankyo 4Q Japan Business Unit Revenue Y95.0B Vs Y91.2B Moomoo
Daiichi Sankyo Company: Strong oncology-driven growth continues, with ambitious targets set for 2...
Japan's Daiichi Sankyo unveils five-year business plan focused on oncology innovation - BioSpectr...
Japan's Daiichi Sankyo unveils five-year business plan focused on oncology innovation BioSpectrum Asia
Manufacturing hangover drives Daiichi Sankyo into the red - pharmaphorum
Manufacturing hangover drives Daiichi Sankyo into the red pharmaphorum
Daiichi Sankyo and Waiv partner for ADC biomarkers - Pharmaceutical Technology
Daiichi Sankyo and Waiv partner for ADC biomarkers Pharmaceutical Technology
Daiichi Sankyo posts 'extraordinary loss' of nearly $1B after overestimating need for ADC capacit...
Daiichi Sankyo posts 'extraordinary loss' of nearly $1B after overestimating need for ADC capacity Endpoints News
Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild - Fierce Pharma
Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild Fierce Pharma
Daiichi Sankyo Waiv Alliance Ties AI Pathology To ADC Valuation Story - simplywall.st
Daiichi Sankyo Waiv Alliance Ties AI Pathology To ADC Valuation Story simplywall.st
Daiichi Sankyo FY2025 slides: oncology surge drives 12.6% growth - Investing.com
Daiichi Sankyo FY2025 slides: oncology surge drives 12.6% growth Investing.com
Daiichi Sankyo Company: Strong oncology-driven growth and ambitious 2030 targets define the new f...
Daiichi Sankyo Co Ltd - To Cancel 31,457,200 Shares, 1.73% Of Issued Shares - TradingView
Daiichi Sankyo Co Ltd - To Cancel 31,457,200 Shares, 1.73% Of Issued Shares TradingView
Daiichi Sankyo shares slip after delaying annual earnings report - BioSpace
Daiichi Sankyo shares slip after delaying annual earnings report BioSpace
Daiichi Sankyo's Attributable Profit Falls 12% in Fiscal Year 2025 - marketscreener.com
Daiichi Sankyo's Attributable Profit Falls 12% in Fiscal Year 2025 marketscreener.com
Is It Time To Revisit Daiichi Sankyo (TSE:4568) After This Year’s 26% Share Price Slide? - simply...
Is It Time To Revisit Daiichi Sankyo (TSE:4568) After This Year’s 26% Share Price Slide? simplywall.st
Waiv and Daiichi Sankyo Collaborate on AI-Driven Biomarker Discovery for ADC Development - HLTH
Waiv and Daiichi Sankyo Collaborate on AI-Driven Biomarker Discovery for ADC Development HLTH
In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to bevera...
In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory Fierce Pharma
FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate - BioSpace
FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate BioSpace
Earnings call transcript: Daiichi Sankyo Q4 2025 results beat EPS expectations - Investing.com Ca...
Earnings call transcript: Daiichi Sankyo Q4 2025 results beat EPS expectations Investing.com Canada
Daiichi Sankyo Company: FY 2025 profit forecast lowered due to ADC supply plan changes and CMO co...
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program - ...
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program Business Wire
Waiv enters collaboration with Daiichi Sankyo to deliver AI-derived biomarkers for ADC programme ...
Waiv enters collaboration with Daiichi Sankyo to deliver AI-derived biomarkers for ADC programme BioSpectrum Asia
Merck : Statement on Daiichi Sankyo Update to Manufacturing and Supply Plan - Merck.com - markets...
Merck : Statement on Daiichi Sankyo Update to Manufacturing and Supply Plan - Merck.com marketscreener.com
Evaluating Daiichi Sankyo (TSE:4568) As Oncology Expectations Fuel Undervaluation Claims - simply...
Evaluating Daiichi Sankyo (TSE:4568) As Oncology Expectations Fuel Undervaluation Claims simplywall.st
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions - Pharmaceutical Technology
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions Pharmaceutical Technology
Daiichi Sankyo To Divest OTC Business - DCAT Value Chain Insights
Daiichi Sankyo To Divest OTC Business DCAT Value Chain Insights
Daiichi Sankyo : Listed on the Dow Jones Best-in-Class Asia Pacific Index - marketscreener.com
Daiichi Sankyo : Listed on the Dow Jones Best-in-Class Asia Pacific Index marketscreener.com
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncolo...
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology PR Newswire
Orchestrating Hope: The Role of a Medical Affairs Leader - Daiichi Sankyo US
Orchestrating Hope: The Role of a Medical Affairs Leader Daiichi Sankyo US
Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline - BioSpace
Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline BioSpace
Daiichi Sankyo and Tempus AI collaborate on ADC clinical development - Pharmaceutical Technology
Daiichi Sankyo and Tempus AI collaborate on ADC clinical development Pharmaceutical Technology
Daiichi Sankyo Co Ltd - Occurrence of losses related to review of product supply plans - marketsc...
Daiichi Sankyo Co Ltd - Occurrence of losses related to review of product supply plans marketscreener.com
Is It Time To Reconsider Daiichi Sankyo Company (TSE:4568) After Recent Share Price Weakness? - Y...
Is It Time To Reconsider Daiichi Sankyo Company (TSE:4568) After Recent Share Price Weakness? Yahoo Finance
Daiichi Sankyo : Announces Occurrence of Losses Related to Review of Product Supply Plans and Rev...
Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance - F...
Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance Fierce Pharma
Daiichi Sankyo gears up for five ADC launches in 2026 - pharmaphorum
Daiichi Sankyo gears up for five ADC launches in 2026 pharmaphorum
Daiichi Sankyo tallies $1.9B in planned Enhertu manufacturing investments: Nikkei - Fierce Pharma
Daiichi Sankyo tallies $1.9B in planned Enhertu manufacturing investments: Nikkei Fierce Pharma
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Ther...
HER2 in Gynecologic Cancers—Why It Matters - Daiichi Sankyo US
HER2 in Gynecologic Cancers—Why It Matters Daiichi Sankyo US
FDA Priority Review And New Alliances Reshape Daiichi Sankyo Growth Story - Yahoo Finance
FDA Priority Review And New Alliances Reshape Daiichi Sankyo Growth Story Yahoo Finance
Daiichi Sankyo postpones annual results, stock dips - Endpoints News
Daiichi Sankyo postpones annual results, stock dips Endpoints News
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo - PR Newswire
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo PR Newswire
Is Now The Right Time To Reassess Daiichi Sankyo (TSE:4568) After Recent Share Price Weakness? - ...
Is Now The Right Time To Reassess Daiichi Sankyo (TSE:4568) After Recent Share Price Weakness? Yahoo Finance
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority - Pharmaceutical Technology
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Pharmaceutical Technology
Daiichi Sankyo Deepens Biologics Push As ENHERTU Faces FDA Decision - Yahoo Finance
Daiichi Sankyo Deepens Biologics Push As ENHERTU Faces FDA Decision Yahoo Finance
Reimagining Cancer Care: Why We Can Not Accept the Status Quo - Daiichi Sankyo US
Reimagining Cancer Care: Why We Can Not Accept the Status Quo Daiichi Sankyo US
How Daiichi Sankyo modernized drug discovery using AWS Parallel Computing Service | Amazon Web Se...
How Daiichi Sankyo modernized drug discovery using AWS Parallel Computing Service | Amazon Web Services Amazon Web Services (AWS)
Is Daiichi Sankyo Now an Opportunity After a 26% Share Price Slide? - Yahoo Finance
Is Daiichi Sankyo Now an Opportunity After a 26% Share Price Slide? Yahoo Finance
Daiichi Sankyo’s ADC Alliances Test Valuation Gap In Oncology Strategy - Yahoo Finance
Daiichi Sankyo’s ADC Alliances Test Valuation Gap In Oncology Strategy Yahoo Finance
A Look At Daiichi Sankyo Company (TSE:4568) Valuation As Oncology Pipeline Drives Undervalued The...
A Look At Daiichi Sankyo Company (TSE:4568) Valuation As Oncology Pipeline Drives Undervalued Thesis Yahoo Finance
Assessing Daiichi Sankyo (TSE:4568) Valuation After A Year Of Weak Share Price Returns - Yahoo Fi...
Assessing Daiichi Sankyo (TSE:4568) Valuation After A Year Of Weak Share Price Returns Yahoo Finance
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Ta...
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies Yahoo Finance
What is Daiichi Sankyo’s Strategy for Preparing for the JP Morgan Healthcare Conference? - Pharma...
What is Daiichi Sankyo’s Strategy for Preparing for the JP Morgan Healthcare Conference? Pharmaceutical Executive
Daiichi Sankyo stock tumbles on results delay, provision - Investing.com
Daiichi Sankyo stock tumbles on results delay, provision Investing.com
Daiichi Sankyo posts 1.4 trillion won loss after revising ADC strategy - CHOSUNBIZ - Chosunbiz
Daiichi Sankyo posts 1.4 trillion won loss after revising ADC strategy - CHOSUNBIZ Chosunbiz
What is Daiichi Sankyo’s Post JP Morgan Strategy? - Pharmaceutical Executive
What is Daiichi Sankyo’s Post JP Morgan Strategy? Pharmaceutical Executive
Daiichi Sankyo Shares Fall After Delaying Earnings Results - Bloomberg.com
Daiichi Sankyo Shares Fall After Delaying Earnings Results Bloomberg.com
4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers fo...
Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $...
Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $41.8M verdict Fierce Pharma
SylamoreBio Announces Research Collaboration With Daiichi Sankyo to Advance SyLEC™ Delivery Techn...
Daiichi Sankyo Partnering With ATLATL Innovation Center to Accelerate APAC Biotech Innovation - C...
Daiichi Sankyo Partnering With ATLATL Innovation Center to Accelerate APAC Biotech Innovation Contract Pharma
Daiichi Sankyo Taps Imagene AI for Biomarker Discovery - BioPharm International
Daiichi Sankyo Taps Imagene AI for Biomarker Discovery BioPharm International
Daiichi Sankyo Leverages AI to Strengthen ADC Clinical Strategy - BioPharm International
Daiichi Sankyo Leverages AI to Strengthen ADC Clinical Strategy BioPharm International
Eyes on Asia: Takesa, Daiichi Sankyo, Biogen - BioXconomy
Eyes on Asia: Takesa, Daiichi Sankyo, Biogen BioXconomy
AstraZeneca, Daiichi Sankyo Move Enhertu to First-Line Metastatic Breast Cancer - BioSpace
AstraZeneca, Daiichi Sankyo Move Enhertu to First-Line Metastatic Breast Cancer BioSpace
Is Daiichi Sankyo (TSE:4568) Using MNM Delivery To Quietly Reframe Its Oncology Innovation Story?...
Is Daiichi Sankyo (TSE:4568) Using MNM Delivery To Quietly Reframe Its Oncology Innovation Story? simplywall.st
Ex-Novartis CMO John Tsai joins Daiichi Sankyo - pharmaphorum
Ex-Novartis CMO John Tsai joins Daiichi Sankyo pharmaphorum
Daiichi Sankyo pens pact with Germany's Gaia to sell digital therapeutic for high cholesterol - F...
Daiichi Sankyo pens pact with Germany's Gaia to sell digital therapeutic for high cholesterol Fierce Biotech
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Tr...
Daiichi Sankyo announces first patient dosed in Phase III trial of Enhertu - Clinical Trials Arena
Daiichi Sankyo announces first patient dosed in Phase III trial of Enhertu Clinical Trials Arena
Is Daiichi Sankyo (TSE:4568) Offering Value After Its Recent Share Price Slide? - simplywall.st
Is Daiichi Sankyo (TSE:4568) Offering Value After Its Recent Share Price Slide? simplywall.st
Is Daiichi Sankyo (TSE:4568) Undervalued After Recent Share Price Weakness? A Fresh Look at Its 2...
Is Daiichi Sankyo (TSE:4568) Undervalued After Recent Share Price Weakness? A Fresh Look at Its 2028 Outlook Yahoo Finance
Suntory to buy Daiichi Sankyo OTC unit for $1.2 bln - Nikkei - Investing.com
Suntory to buy Daiichi Sankyo OTC unit for $1.2 bln - Nikkei Investing.com
AZ/Daiichi's Enhertu lands earlier-line Korean approvals in HER2 breast and gastric cancers - kor...
AZ/Daiichi's Enhertu lands earlier-line Korean approvals in HER2 breast and gastric cancers koreabiomed.com
ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation - Yahoo Finance
ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation Yahoo Finance
Daiichi Sankyo shares slide to 4-yr low after co delays annual earnings - Investing.com
Daiichi Sankyo shares slide to 4-yr low after co delays annual earnings Investing.com
Lunit and Daiichi Sankyo Form Collaboration to Advance Research and Discovery for AI-Driven Bioma...
Lunit and Daiichi Sankyo Form Collaboration to Advance Research and Discovery for AI-Driven Biomarkers and Translational Oncology Pharmaceutical Executive
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target ...
Culture-Driven Talent Acquisition: How Daiichi Sankyo Builds Teams - Daiichi Sankyo US
Culture-Driven Talent Acquisition: How Daiichi Sankyo Builds Teams Daiichi Sankyo US
BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development T...
Daiichi Sankyo’s enduring tie to DC’s Cherry Blossom Festival (SPONSORED CONTENT) - DC News Now
Daiichi Sankyo’s enduring tie to DC’s Cherry Blossom Festival (SPONSORED CONTENT) DC News Now
John Tsai joins Daiichi Sankyo as global head of R&D - The Pharma Letter
John Tsai joins Daiichi Sankyo as global head of R&D The Pharma Letter
Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Tech...
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC - BioSpace
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC BioSpace
AstraZeneca And Daiichi Sankyo Stack The Odds For Datroway’s Lung Cancer Bets - Citeline News & I...
AstraZeneca And Daiichi Sankyo Stack The Odds For Datroway’s Lung Cancer Bets Citeline News & Insights
AstraZeneca–Daiichi Sankyo’s ADC, Enhertu, Gets FDA Priority Review in Early Breast Cancer - BioP...
AstraZeneca–Daiichi Sankyo’s ADC, Enhertu, Gets FDA Priority Review in Early Breast Cancer BioPharm International
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe...
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe Business Wire
Daiichi Sankyo: Hit On Multiple Fronts, But Shares Look Undervalued (OTCMKTS:DSNKY) - Seeking Alpha
Daiichi Sankyo: Hit On Multiple Fronts, But Shares Look Undervalued (OTCMKTS:DSNKY) Seeking Alpha
Daiichi Sankyo (TSE:4568) Earnings Growth Slows to 11.8%, Testing Recent Bullish Narratives - Yah...
Daiichi Sankyo (TSE:4568) Earnings Growth Slows to 11.8%, Testing Recent Bullish Narratives Yahoo Finance
Play "Musc Box Dancer" Wooden Musc Box Wth Sankyo Muscal Movement - aviglianonews.it
Play "Musc Box Dancer" Wooden Musc Box Wth Sankyo Muscal Movement aviglianonews.it
Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologic...
Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Disco...
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advanc...
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd - BioSpace
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd BioSpace
Daiichi Sankyo transfers healthcare unit to Suntory - The Pharma Letter
Daiichi Sankyo transfers healthcare unit to Suntory The Pharma Letter